Stock:
Symbol Lookup
Register | Login
...
History
...
...

Pre Market | Dow Jones | Gold | Newsletters | Learn


OPKO Health - OPK - To acquire Cytochroma Inc.

Wednesday, January 9, 2013 11:47 AM
OPKO Health, Inc. (NYSE:OPK) has entered into a definitive agreement to acquire Cytochroma Inc. (Markham, Canada) whose lead products, both in phase 3 clinical trials, are Replidea™ (coded CTAP101 Capsules), a vitamin D prohormone to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen™, a non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients. Replidea™ has been shown in a phase 2b clinical trial to effectively and safely treat SHPT and the underlying vitamin D insufficiency in pre-dialysis patients. Vitamin D insufficiency arises in CKD due to the abnormal upregulation of CYP24, an enzyme which destroys vitamin D and its metabolites. Studies in CKD patients have demonstrated that currently available over-the-counter and prescription vitamin D products cannot reliably raise blood vitamin D prohormone levels or effectively treat SHPT. "OPKO intends to market Replidea™ along with our proprietary point-of-care vitamin D diagnostic test currently in development," stated Phillip Frost, MD, CEO and Chairman. "We envision these remarkable products as part of the foundation for a new and markedly improved standard of care for chronic kidney disease patients having SHPT and/or hyperphosphatemia." Alpharen™ has been shown safe and effective in treating hyperphosphatemia in the phase 2 and 3 clinical trials undertaken to date in dialysis patients. Hyperphosphatemia (elevated serum phosphorus) exacerbates SHPT and promotes bone disease, soft tissue mineralization and progression of kidney disease. Approximately 90% of dialysis patients in the United States require regular treatment. Cytochroma's officers, including Charles W. Bishop, PhD, CEO, an authority on developing and commercializing successful new vitamin D therapies, and Eric J. Messner, MBA, having a noteworthy track record in pharmaceutical business development and in marketing and sales in the CKD arena, will join the OPKO management team. Prior to Cytochroma, Dr. Bishop and Mr. Messner held key positions at Bone Care International, Inc., a leader in vitamin D therapeutics acquired by Genzyme Corporation, now a division of Sanofi. About Cytochroma Cytochroma is a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and SHPT associated with CKD.  About OPKO Health, Inc. - OPK OPKO (OPK) is a multinational biopharmaceutical and diagnostics company that seeks to establish industry leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.
PRINT

FREE Options Trading Lessons
I'll show you how to unlock HUGE Gains with Options Trading
Let's make 2014 the year you get RICH!

Latest Headlines

Canada unveils plan to auction wireless spectrumCanada unveils plan to auction wireless spectrum
TORONTO (Reuters) - The Canadian government unveiled a major update to its plan to allocate airwaves for mobile use on Thursday, and said an auction of high-frequency AWS-3 spectrum will begin on Marc...
EU leaders seek to overcome hostility to U.S. trade dealEU leaders seek to overcome hostility to U.S. trade deal
BRUSSELS (Reuters) - EU leaders defended plans for the world`s biggest trade deal with the United States, seeking on Thursday to counter hostility in Europe and clear the way for the accord to be ag...
Capital for EU investment fund not to clash with EU fiscal rules: EU summitCapital for EU investment fund not to clash with EU fiscal rules: EU summit
BRUSSELS (Reuters) - The European Commission told European Union leaders on Thursday it would treat favourably any capital governments inject into an EU investment fund when it assesses every country`...
Icahn offers $20 million to keep Atlantic City Trump casino openIcahn offers $20 million to keep Atlantic City Trump casino open
(Reuters) - Billionaire investor Carl Icahn offered to lend $20 million to help bankrupt casino operator Trump Entertainment Resorts Inc keep its Trump Taj Mahal casino in Atlantic City open. "Even ...
Goldman's Waldron promoted to co-head of investment bankingGoldman's Waldron promoted to co-head of investment banking
NEW YORK (Reuters) - Goldman Sachs Group Inc <GS.N> has promoted John Waldron to co-head of its investment banking business, replacing John S. Weinberg, a vice chairman whose family has been i...

Loading Headlines...
 

Stock Market

Track the stock market today with the latest news and information on all things investing! Watch your stocks perform throughout the day and watch the breaking stock market news.

Feedback | disclaimer | privacy policy

Stock Market News

The Stock Market is ever changing. Keep up on your stock market news.

Stock Market Newsletters

Read up on your favorite stock market newsletters.


Learn the Stock Market

Sharper your stock trading skills with our stock market education section.

Algorithm Based
Trade Signals
arrow
small cap swing trades SmallCaps stocks under $10
Index Signals Index Signals SPY, QQQ, DIA, IWM
options trading Mega Stocks options + stock trade signals
Forex Forex Signals major FX pairs signals